title: [The effect of active immunization with a conjugate of dopamine and bovine serum albumin on the development of an experimental MPTP-induced depressive syndrome and on the monoamine metabolism in the brain of rats].
abstract: Active immunization with dopamine conjugated with bovine serum albumin (DA-BSA) or BSA with complete Freund's adjuvant (CFA) partly suppressed the development of the MPTP-induced depressive syndrome in rats preventing the appearance of "behavioral despair" symptoms: increase in immobility time and higher index of depression in forced-swim test. In DA-BSA-immunized rats the content of DOPA, DA, HVA, NA, and 5-HN in caudate putamen and that of NA in the frontal cortex was increased, while in BSA-immunized rats the content of 5-HT in both brain areas and that of DOPAC in the frontal cortex was decreased both in rats with reduced depressive syndrome and in saline control as compared with intact animals a day after the last drug injection. In DA-BSA-immunized rats with reduced depressive syndrome the increase in DA and 5-HT content in caudate putamen was less expressed and DOPAC content was lower than in saline control. In BSA-immunized depressive rats DA content in the frontal cortex was also reduced as compared to control.
authors.affiliation: Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow.
authors.forename: N A
authors.initials: NA
authors.lastname: Krupina
authors.forename: E V
authors.initials: EV
authors.lastname: Popkova
authors.forename: I N
authors.initials: IN
authors.lastname: Orlova
authors.forename: L A
authors.initials: LA
authors.lastname: Vetrilé
authors.forename: G N
authors.initials: GN
authors.lastname: Kryzhanovskiĭ
authors.forename: L A
authors.initials: LA
authors.lastname: Basharova
authors.forename: V A
authors.initials: VA
authors.lastname: Evseev
authors.forename: T E
authors.initials: TE
authors.lastname: Iordanskaia
authors.forename: N B
authors.initials: NB
authors.lastname: Pankova
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000818:Animals; D015306:Biogenic Monoamines / Q000378:metabolism*; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D001923:Brain Chemistry / Q000187:drug effects / Q000502:physiology; D003866:Depressive Disorder / Q000209:etiology* / Q000378:metabolism; D004195:Disease Models, Animal; D004298:Dopamine / Q000276:immunology*; D015259:Dopamine Agents; D004306:Dose-Response Relationship, Immunologic; D005620:Freund's Adjuvant / Q000276:immunology; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D012710:Serum Albumin, Bovine / Q000276:immunology*; D014611:Vaccination / Q000379:methods*; D018074:Vaccines, Conjugate / Q000276:immunology
chemical_list: D015306:Biogenic Monoamines; D015259:Dopamine Agents; D018074:Vaccines, Conjugate; D012710:Serum Albumin, Bovine; D005620:Freund's Adjuvant; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D004298:Dopamine